Greenlight Guru is the only quality management software designed specifically for the medical device industry.
Get to market faster with less risk and achieve true quality.
The seeds for Greenlight Guru were planted back in 2006 by Jon Speer, a medical device engineer turned consultant as a result of a simple observation: paper-based quality management systems are painful, risky & wildly inefficient. Commercial quality management software solutions have been available for over 20 years now, yet only about 30 percent of medical device companies that should be using them were. This observation and question led Jon Speer to team up with David DeRam to create the vision for a beautifully simple quality management software.
Greenlight Guru partners with trade publications and frequently hosts webinars to help medical device startup founders plot a clear course through the complicated regulatory environment.
Quality management solutions existed, or could be engineered to work, for nearly every industry. Because of to the complicated nature of medical device regulatory compliance in the United States, Canada and the European Union one of two things was happening: 1. Systems not meant for medical devices were being rigged to work or, 2. An unorganized, not easily searched paper-based QMS was developed.
Greenlight Guru was developed to help medical device manufacturers manage documents, manage risk, perform quality management and log and address customer complaints in an easy to use cloud-based platform.
Who are your competitors?
Greenlight Guru is the only QMS system built specifically for the medical device industry. Non-industry specific QMS systems exist; however, they often have to be heavily modified to handle even the most mundane tasks in the medical device industry. As a result, Greenlight Guru helps device manufacturers spend more time on their product, and less time on paperwork.
How your company differentiates itself from the competition and what differentiates Greenlight Guru?
Greenlight Guru consists of three systems meant to help device manufacturers “GO” to market, “GROW” in the market, and “GURU” to provide regulatory expertise to device makers. This three pronged approach helps manufacturers through the full life-cycle of the product.
Greenlight Guru has a B2B business model with systems mean to help device makers “GO” to market, “GROW” in the market and “GURUs” to help stay in the market.
Greenlight Guru is always looking for talented individuals with a willingness to work hard and improve the quality of life for our users.
YourDoctors.Online provides patients direct access to the North American doctors. The company’s general physicians are available online to answer any general inquiry and experienced specialists for second opinions.
We are like WebMD but with a personal touch. Connect with a personal doctor 24/7 to get personalized answers to your medical questions with an “opinion that matters.”
CEO Nauman Jaffar’s mother, aunt and boss were diagnosed with chronic diseases. Some survived due to on-time proper diagnosis while others were not that lucky. This motivated him to leave my corporate life and create a solution that connects global patients to world-class doctors. Our mission is to develop a social enterprise focused on preventing misdiagnosis and ensuring that excellent healthcare is a “click” away. We aspire to save one life at a time with medical “opinion that matters”.
YourDoctors.Online is directly reaching out to consumers all across the world to connect patients with internet access to North American doctors get access to the best medical advice. We communicate through a variety of digital channels to not only stay top of mind but to gain awareness that getting the right medical advice is a few clicks away.
Our target audience and marketing focus is towards women from the ages between 20-35 and who for an online doctor service for their family.
Who are your competitors?
Because of the service YourDoctors.Online provides, we have no direct competitors. Companies, such as Best Doctors, 2nd.MD, do offer a similar service; however, instead of directly targeting companies and their employees, we directly going out to consumers. As a result, our patients are from 125 different countries.
How your company differentiates itself from the competition and what differentiates YourDoctors.Online?
With direct access to our customer, our competitive advantages is our brand value and our valued pricing for a medical second opinion. Since our market is international patient with various different affordability ranges, we provide our patients with access to doctors at affordable rates.
We have three different tiers of services such as 1) specialist who provide a medical second opinion for a premium price; 2) for our monthly members who get access to our auxiliary medical practitioners (i.e. psychologist, nutritionist, etc.); and 3) free access to our general physicians.
Intiva Health is the first truly integrated career platform for healthcare professionals. It redefines the medical credentialing process by making it faster, more efficient and more secure.
Intiva Health provides healthcare professionals with a single place to manage their credentials,continuing education, new job opportunities, secure messaging needs and more. It is built on the Hashgraph digital ledger platform, which means it is faster, more secure, and more error proof than blockchain.
Intiva Health was founded in 2006 as a staffing agency for surgical services and emergency rooms. Today the Austin, Texas company it has reinvented itself as a digital health startup featuring a next generation blockchain technology that cuts the time it takes for the medical credentialing process from months to seconds, improves HIPAA compliance,and makes document tampering or theft almost impossible.
Intiva Health focuses its marketing and PR efforts on licensed medical professionals (LMPs), practice managers, and the facilities where they work including medical groups, hospitals and professional associations.The company launched a new brand awareness campaign in March 2018 that included the introduction of the Intiva Token, a new cryptocurrency that LMPs can use to purchase continuing education classes, cyber insurance and other services.
Intiva is also partnering with the National Osteoporosis Foundation to test the advantages of using the IntivaToken for charitable donations.
The Intiva Health Platform automates the burdensome tasks of credential and licensure management, continuing education, and discovering job opportunities for healthcare professionals. Intiva Health’s new ReadyDoc™credential verification solution, built on top of the Hashgraph distributed ledger technology, disrupts the existing broken, slow, and error-prone healthcare credentialing system, which today can take weeks or months to verify credentials, and is subject to tampering.
Intiva believes that ReadyDoc can replace the current processes of credentialing and primary source verification by storing documents and credentials in a Hashgraph-based distributed ledger. Providers and facilities can obtain information that is pre-verified, securely stored, and readily available, creating an ongoing, self-auditing verification of provider work history and clinical reputation.
ReadyDoc will act fluidly between health systems and facilities across the U.S., allowing organizations to instantly verify work history and clinical reputations. In the event of an emergency like the Houston hurricane, facilities will be able staff up by vetting the credentials of qualified providers instantly. ReadyDoc eliminates redundancy and the need for third party verification organizations, letting medical professionals get to work sooner.
Babyscripts is a virtual care platform for prenatal care powered by mobile apps that drive better patient decision making, IOT devices for remote monitoring, and a host of population health tools to give providers access to patient data in real time.
It seems unlikely that two childless bachelors, with no healthcare experience, would start a pregnancy company, but Juan Pablo Segura and Anish Sebastian founded Babyscripts, now the most impactful digital health tool in the obstetrical market. In 2014, with a passion to improve the current healthcare system due to family health struggles, business savvy, and the tenacity to succeed, these two former Deloitte consultants found themselves in front of the Chair of Obstetrics at George Washington School of Medicine & Health Sciences, Dr. Nancy Gaba, which started the journey of Babyscripts.
Babyscripts sells to health systems, private practices, and payers to support women’s health initiatives in pregnancy care. Babyscripts is then delivered by a care provider to an expectant mother at the beginning of her pregnancy. It is deployed through risk-specific modules that are tied to the clinical/social risk of a patient at the point of care.
Each year, 4 million babies are born in the United States. Babyscripts works with the providers of care for these pregnancies – health systems and private practices – to support better access to care and better quality of care. Currently, nearly half of the counties in the United States don’t have access to an OB-GYN, according to the American College of Nurse-Midwives. The American Congress of Obstetricians and Gynecologists estimated that in 2020, there will be between 6,000 and 8,000 fewer OB-GYNs in the country than needed. Babyscripts is the only clinically validated tool that allows doctors to automate aspects of care, enabling there to be greater efficiency in the workflow, enabling doctors to touch more patients in a meaningful way.
Who are your competitors?
Our competition can be categorized in a few areas:
There are Consumer Maternity Apps in the market (ex. What to Expect, BabyCenter, The Bump)
Payer focused apps and programs for maternity (Wildflower Health, Ovia Pregnancy)
Non-Obstetric based clinical apps (ex. Wellpass, Vivify Health, Conversa Health)
How your company differentiates itself from the competition and what differentiates Babyscripts?
Babyscripts is the only platform that connects the clinical provider and patients together using technology, while at the same time lowering the cost of care. By including the provider and all of their guidance, specific information and advice into the equation, it ensures that a patient is getting information that aligns with her provider’s care plan, while keeping engagement high. Additionally, Babyscripts is the only clinical tool that is singularly focused on solving obstetrical problems.
Dthera digitized reminiscence therapy to enable people with dementia to see and hear their family and friends share familiar stories with them. Our first product, ReminX, is an artificial intelligence-powered consumer health product designed to improve the quality of life in individuals suffering from neurodegenerative diseases, such as dementia and Alzheimer’s disease, as well as seniors experiencing social isolation.
Edward Cox, CEO, and David Keene, CTO, both had an upbringing similar to millions of families around the world – they grew up with a grandparent in the home. The special relationships with their grandparents included time hearing stories from the Greatest Generation – from growing up in humble beginnings to traveling across continents for war, peace, work, love and family. At the time, they didn’t realize they were engaging in reminiscence therapy, but did realize the impact social isolation can have on the elderly, especially those suffering from dementia or Alzheimer’s disease. With ReminX, their goal is to improve the quality-of-life for millions of elderly suffering from dementia by digitizing and proactively advocating reminiscence therapy and making it available to all.
Researchers concluded that ReminX holds great promise for bringing reminiscence therapy to people suffering from dementia. Dthera is exploring additional collaborations with non-profit organizations, medical centers and elder care facilities. ReminX is available for purchase by families, caregivers and administrators at senior assistant living centers through direct response marketing. Complete this form to find out where to purchase ReminiX.
Our target market is the 46.8 million people worldwide living with dementia from Alzheimer’s, as well as from other neurodegenerative conditions. In the US alone, the Alzheimer Association estimated 5.7 million Americans have the disease and the cost to care for Alzheimer’s and other dementias will reach more than $277 billion in 2018. Dthera is focused on creating and delivering digital therapeutics that bring medically- validated treatments, such as reminiscence therapy, to patients suffering from dementia and severe forms of social isolation, to ease symptoms and create a better quality-of-life for them and their caregivers.
Who are your competitors?
In the digital therapeutics space, we are one of the only companies developing products for the elder care market, including dementia patients, but also people suffering from extreme social isolation.
As far as products to reach this group of the elderly, other tablets, social media or photo sharing sites could seem to be competitors with ReminX, but these products are not actually suited to this patient market. Apps and most tablets are too complicated for patients suffering from dementia to use, and none of these vehicles have active involvement of family members in the story-creation process designed into them. ReminX proprietary software includes an AI-interface app that engages family members to upload content and then optimizes it, and proprietary facial recognition software in the tablet provides feedback on what’s most effective.
Dthera designed ReminX with the elderly, their caregivers and families in mind. It automatically creates elegant documentary-like videos and plays stories on demand. There is no interface to learn, simply picking up the tablet starts stories and setting it down stops them.
With a mission to improve the lives of people living with diabetes and chronic conditions worldwide, Fit4D delivers scalable and effective programs through an optimized mix of technology human-based interactions.
At just 36 years old, David Weingard was diagnosed with Type 1 diabetes. With no family history of diabetes, he was confused and overwhelmed about the diagnosis. He had two sessions with his doctor on how to use insulin and that was it. Having received limited support and education on his diagnosis, Weingard was left to manage his diabetes on his own and needed help.
He then found Cecilia, a certified diabetes educator (CDE), who compassionately gave him the correct steps to follow to help him become productive again, personally and professionally. Cecilia sparked an idea for Weingard – to scale the personalized coaching he received, to millions of people living with diabetes, but using a technology platform. With the daily vigilance and management of his diabetes, he left his corporate job and founded Fit4D.
Fit4D has established business partnerships with clients that include major health plans and providers such as Humana, HealthFirst and several Blue Cross Blue Shield plans, along with major pharmaceutical and medical device companies. The company delivers scalable and cost-effective diabetes management programs through an optimized mix of human-based touch points and technology to deliver measurable outcomes in an affordable manner.
Fit4D is driving improvements in diabetes outcomes across the socio-economic spectrum, achieving a relatively high enrollment rate, lowering blood sugar levels, and delivering significant cost-savings and ROI for clients.
20 percent increase in adherence leads to three times increase in ROI for pharma/device companies.
One- to two-point reduction in HbA1c levels demonstrates improved health outcomes for enrolled patients.
28 percent enrollment rate saves $380 per patient for payers and providers.
More than 95 percent patient engagement rate
Who are your competitors?
Fit4D is unique in that we scale and deliver personalized one-on-one support through the optimization of human touch and technology. There are other companies in the market that are combining patient healthcare services with a heavy focus on technology, such as Livongo and Omada; however, they don’t offer a personalized patient approach to diabetes. Fit4D emphasis on combining human touch with a dedicated CDE throughout the length of the program, allowing the patient to build a strong fruitful coaching relationship. As a result, our service is highly valued for the likes of payers, providers, pharma and medical device companies.
NeuronUP is an online platform for professionals working in neurorehabilitation and cognitive stimulation with patients with cognitive deficits related to Alzheimer’s, Parkinsons, traumatic brain injury, ADHD, normal aging, etc.
In the United States alone, there are millions of people living with Alzheimer’s,Parkinson´s, traumatic brain injury, Multiple sclerosis, and ADHD. There is an absolute necessity to help rehabilitate people with these conditions and NeuronUP can help.
NeuronUP was born out of the psychology clinic of our boss, CEO and founder, Iñigo Fernández de Piérola. During his work as a psychologist, he realized that a lot of his time was spent making or searching for materials to use with his patients. Much of the content he found online or elsewhere wasn’t very useful, was very expensive or was geared only towards children. Setting out to fix that problem, NeuronUP got its first spark of life.
Being an online platform, NeuronUP puts a lot of energy into SEO to try to capture relevant searches. We get a lot of word of mouth traffic from pleased clients too. Once a month for our Spanish speaking-client base, we host online chats with renowned people working in the neurosciences. NeuronUP Academy is very popular and keeps people coming back to the site. We would like to implement that for our English-speaking clients as well in the future.
Our target audience are the professionals working in neuropsychology, occupational therapy and speech therapy. With the millions of people in the world with cognitive deficits related to neurodegenerative diseases, brain injuries,mental illnesses, neurodevelopmental disorders and mental disabilities, these professionals need and deserve help to save time and energy putting together their rehabilitation strategies.
Who are your competitors?
Our clients are only professionals who can direct the rehabilitation strategy based on what each individual patient needs. Other similar products like BrainHQ and Cognifit will sell to the end user and we feel like that isn’t the best strategy.
How your company differentiates itself from the competition and what differentiates NeuronUP?
Professionals are able to create a strategy easily for each individual patient by working with NeuronUP. Activities such as worksheets, serious games, simulators and content generators can be personalized to the patient for maximum efficacy. Content is also classified by the cognitive function being worked, which allows for rehabilitation at the clinic or at home.
MedPilot uses patient demographic data and payment historyinformation from the practice management system to categorize accounts in order to tailor content, frequency and message medium, boosting engagement rates and patient satisfaction.
MedPilot transforms patient financial care through technology-enabled services.
When Jacob Myers, our CEO, worked as a revenue cycle management consultant he noticed numerous solutions to help providers work with insurance companies, but saw a huge void on the patient side of the equation. MedPilot was founded to help providers more efficiently and effectively work with patients to help them understand and resolve their medical expenses.
MedPilot partners with practice management softwares and revenue cycle companies to help them add value to their provider clients who are interested in better patient solutions.
Because of changes in the health insurance landscape, patients now account for more than 30 percent of healthcare payments. Providers used to overlook patients and only focus on collecting from insurance companies, however now patients can no longer be ignored.
Who are your competitors?
Most healthcare providers engage revenue cycle companies who specialize in insurance billing to also manage patient balances. The old school manual methods of working with patients is time-intensive and laborious, so these vendors don’t put a lot of effort into helping patients.
How your company differentiates itself from the competition and what differentiates MedPilot?
Typically, revenue cycle teams only utilize costly patient statements and occasional phone calls. Now close your eyes and picture the exact opposite …
MedPilot pulls in patient demographic information and billing data from the practice management system into our platform. Our software then uses data science and behavioral targeting to inform our specialized Patient Services team on the best times and frequencies for phone calls, texts, emails and statements to drive patients to our proprietary online bill pay.
For example, if a patient drops off on our help center, we would pause statements and prioritize their account to receive a call from our smart dialer, saving money, resolving the account quicker and increasing patient satisfaction.
MedPilot’s business model is a percent of successful transactions on our platform when working with healthcare providers directly. We utilize a licensing fee-model when engaging with RCM and practice management companies.
GlucoMe enhances the way diabetes patients and medical teams work together by changing the traditional face-to-face diabetes care paradigm with an AI-enabled digital diabetes clinic.
The number of diabetes professionals has remained flat over the last decade. Conversely, the population of those with diabetes is growing. GlucoMe makes it possible for diabetes professionals to successfully manage this growing population by treating the right patients, at the right time, at the right cost, no matter their location and provide effective and continuous care to up to 10X more diabetes patients than with the current standard of care. The solution encourages a combination of face-to-face in-clinic and digital (virtual) visits enabling ongoing communication, treatment changes as necessary and immediate intervention as required.
Dov Moran is one of Israel’s most prominent hi-tech leaders, entrepreneurs and investors. He is known as the inventor of the USB memory drive (sold his company M-systems to SanDisk for $1.6B). In addition, Dov was the Founder and CEO of Modu, which developed a revolutionary modular phone (acquired by Google in 2011. Modu’s assets are the basis for Google’s modular phone Project Ara).
Yiftah Ben Aharon is a technology executive. He was head of R&D for the machine learning investment fund and led software development at Modu after serving in the IDF’s elite 8200 intelligence unit.
Moran is diabetes T2 patient and faces the challenges of diabetes management daily. Ben-Aharon has a parent with diabetes. He is a primary caregiver and is deeply involved in the diabetes monitoring loop. One day they were discussing how it was possible that in the era of smart technologies, diabetes patients were still facing the challenge of clinical data availability. Some of the smart monitors that were available in the market were expensive and practically available to only around 25% of diabetes patients globally. That was the starting point for solving the connectivity issue to ensure the continuum of clinical data for professional analysis and for all patients.
Moran and Ben Aharon started with developing smart monitors for their own use. They shared their invention with others. The feedback was so encouraging and enthusiastic that they started a company. GlucoMe began with providing clinical data, thereafter analysis functions and later developed its AI platform. Today GlucoMe is an end-to-end solution that includes diabetes monitors, a mobile app and a digital diabetes clinic with software for healthcare professionals.
GlucoMe provides healthcare providers and insurance companies with new digital capabilities to easily review and assess massive quantities of data – real-time information, trends, analysis, treatment recommendations – and treat for up to 10 times more patients than they could with only face-to-face office visits.
In 2017, diabetes expenditure came to some $727 billion, and is expected to increase to around $776 billion during the coming two decades. In 2017, an estimated 8.8 percent of the adult population worldwide had diabetes. However, the number of healthcare providers worldwide has either not increased at all in certain areas or not increased nearly enough to provide adequate attention to the growing number of patients who have diabetes. Until now, it’s been an uphill battle. GlucoMe’s technological advances have made it possible to make this ratio work.
Who are your competitors?
GlucoMe has several competitors on different aspects of the solution whether is it software or hardware. Companies like Glooko, Livongo, One Drop and alike can be considered GlucoMe’s competitors. All are US companies, which are for the most part not currently active outside of the US.
How your company differentiates itself from the competition and what differentiates GlucoMe?
Some of the competitors are mostly the device companies and some are coming from the software direction. There are several parameters that can differentiate GlucoMe from competition: affordability of the GlucoMe’s monitors, their universality, simplicity of operation and connectivity (GlucoMe’s BGM is the only one to transfer data to both iOS and Android through its microphone. It does this using audio connectivity), in addition to several software features where GlucoMe is leading the way.
Vyasa Analytics provides a highly scalable deep learning platform for organizational data, enabling conceptual querying and collaborative analytics to help inform key decisions derived from your most valuable information assets.
Vyasa Analytics provides deep learning software and analytics for life sciences and healthcare organizations
Dr. Christopher Bouton earned his Ph.D. in molecular neurobiology from Johns Hopkins University and sold his first big data software company, Entagen, to Thompson Reuters in 2013. Living in India for four years as a boy, he developed a great respect for Vyasa – an important Hindu figure, storyteller and compiler of information – and believes that AI approaches will help us better compile and gain insights from our data systems. In 2016, he founded Vyasa Analytics to apply AI in life sciences and healthcare.
Vyasa engages with life sciences and healthcare organizations to educate the industry about deep learning technologies, including speaking alongside executives at conferences and events. Dr. Bouton is also a frequent contributor and commentator to industry publications.
In 2016, the pharmaceutical industry spent some $157 billion on research and development. This figure is set to increase to more than $180 billion by 2022. The healthcare analytics market was $8.69 billion by 2016 and is estimated to reach $33.38 billion by 2022.
Vyasa is positioned to capture hundreds of millions of dollars in these markets by allowing organizations to conduct analytics on data relevant to their research. Other analytics companies in the space experiencing rapid growth include Lattice.io (acquired by Apple for $200 million), BenevolentAI (valued at $1.7 billion) and Exscientia (recent deals with GSK for $43 million and Sanofi for $273 million).
Who are your competitors?
While there are many deep learning companies, Vyasa is the only one applying deep learning to life sciences and healthcare specifically.
How your company differentiates itself from the competition?
Focusing in the life sciences and healthcare verticals is a key differentiator for Vyasa. In partnership with life sciences and healthcare organizations, we build software to help design better therapeutics, free up researchers for higher-level thinking and solve problems that matter for humanity.
Business model: Vyasa has a B2B business model. Every project is a blend of software licensing and services, provided to the life sciences or healthcare organization to advance their research goals. We are projecting upwards of $3 million in revenue in 2018.